Current developments and perspectives in targeted therapies;Aktuelle Entwicklungen und Perspektiven zielgerichteter Therapien

Onkologie

Volumn 33, Issue SUPPL. 5, 2010, Pages 2-11

  Dickgreber, Nicolas ^a   Huber, Rudolf M ^b   Reck, Martin ^c   Reinmuth, Niels ^d   Schütte, Wolfgang ^e   Serke, Monika ^f   Wolf, Jürgen ^g  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c KRANKENHAUS GROSSHANSDORF   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Hospital Martha Maria Halle Dölau   (Germany)

^f LUNGENKLINIK HEMER   (Germany)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

ALK fusion gene; EGFR mutation; EGFR tyrosine kinase inhibitors; IGFR inhibitors; Maintenance therapy; Non Small Cell Lung Cancer; Tumour vascular disrupting agents; VEGFR tyrosine kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; VASCULAR TARGETING AGENT; VASCULOTROPIN INHIBITOR; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GENETIC MARKER; NEW DRUG; ONCOPROTEIN; PROTEIN TYROSINE KINASE; SOMATOMEDIN RECEPTOR; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; CANCER CHEMOTHERAPY; DRUG TARGETING; GENETIC MARKER; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; REVIEW; AFTERCARE; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; NUCLEOTIDE SEQUENCE; PROGNOSIS; VASCULARIZATION;

AFTERCARE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, SOMATOMEDIN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 77953242701     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313971     Document Type: Review

References (41)

1. Socinski MA, et al.: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advancedstage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:1335-1343.
2. http://clinicaltrials.gov/ct2/show/NCT00976456.
3. Fidias PM, et al.: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598.
4. Ciuleanu T, et al.: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-1440.
5. Cappuzzo F, et al.: SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with firstline platin-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009;27(suppl 15): abstr 8001.
6. Roche Pharma, data on file.
7. Brugger W, et al.: Molecular markers and clinical outcome with erlotinib: results from the phase III placebo-controlled SATURN study of maintenance therapy for advanced NSCLC. San Francisco, World Congress on Lung Cancer 2009;abstr B9,1.
8. Mok TS, et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
9. Yoshioka H, et al.: A phase II trial of erlotinib monotherapy in pretreated patients with advanced nonsmall cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol 2010;5:99-104.
10. Doebele RC, et al.: New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 2010, in press.
11. Smylie M, et al.: A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history. J Clin Oncol 2007;25(suppl 18):abstr 7611.
12. Miller VA, et al.: Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial. J Clin Oncol 2008;26(suppl):abstr 8028.
13. Shih J, et al.: A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUXLung 2). J Clin Oncol 2009;27(suppl 15):abstr 8013.
14. Janne PA, et al.: Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. J Clin Oncol 2008;26(suppl):abstr 8027.
15. Gualberto A, et al.: Molecular signature of NSCLC patients responding to anti-IGF-1R therapy. Mol Markers 2008;abstr 26.
16. Pollak M, et al.: Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-518. (Pubitemid 38868620)
17. Pollak M: Insulin-like growth factor-related signalling and cancer development. Recent Results Cancer Res 2007;174:49-53.
18. Hartog H, et al.: The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007;43:1895-1904.
19. Guix M, et al.: Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118:2609-2619.
20. Karp DD, et al.: Phase II study of the anti-insulinlike growth factor type 1 receptor antibody CP-751 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-2522.
21. www.pfizer.com, Presseinformation 29.12.2009.
22. Clément-Duchêne C, et al.: Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer. J Thorac Oncol 2010;5:129-139.
23. McKeage MJ, et al.: Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-2012.
24. McKeage MJ, et al.: Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/ DMXXA) 1800 mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009;65: 192-197.
25. McKeage MJ, et al.: Comparison of safety and efficacy between squamous and non-squamous nonsmall cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404). J Clin Oncol 2008; 26(suppl):abstr 8072.
26. Heymach J, et al.: Randomized phase II study of vandetanib alone or in combination with carboplatin and paclitaxel as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(suppl 18):abstr 7544.
27. De Boer R, et al.: Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). J Clin Oncol 2009;27(suppl 15):abstr 8010.
28. Herbst RS, et al.: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 2009;27(suppl 18): abstr CRA8003.
29. Natale RB, et al.: Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009;27(suppl 15):abstr 8009.
30. Scagliotti G, et al.: Phase III trial comparing carboplatin and paclitaxel with or without sorafenib in chemonaive patients with stage IIIB (with effusion) or IV non-small cell lung cancer. Geneva, 1st IASLC-ESMO European Lung Cancer Conference, 2008:48.
31. Socinski MA, et al.: Multicenter, phase II trial of sunitinib in previously treated, advanced non-smallcell lung cancer. J Clin Oncol 2008;26:650-656.
32. Brahmer JR, et al.: Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study. J Clin Oncol 2007;25 (suppl 18):abstr 7542.
33. Hilberg F, et al.: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-4782.
34. Von Pawel J, et al.: A double blind phase II study of BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(suppl 18):abstr 7635.
35. Hanrahan EO, et al.: Baseline vascular endothelial growth factor concentration as potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009;15:3600-3609.
36. Lynch TJ, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
37. Mitsudomi T, et al.: Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 2006;11:190-198.
38. Fukuoka M, et al.: Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol 2009;27(suppl 15):abstr 8006.
39. Rosell R, et al.: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
40. Soda M, et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
41. Kwak EL, et al.: Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009;27 (suppl 15):abstr 3509.